Literature DB >> 2208175

Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung.

M Tateishi1, T Ishida, T Mitsudomi, S Kaneko, K Sugimachi.   

Abstract

We immunohistochemically examined 131 primary human lung adenocarcinomas for the possible presence of autocrine factors. Transforming growth factor alpha (TGF alpha) and epidermal growth factor (EGF) were considered growth factors with epidermal growth factor receptor (EGFR) as the receptor. Of these tumors, 87 (66%) showed a high expression of TGF alpha, 66 (50%) showed a high expression of EGF, and 55 (42%) were positive for EGFR reactivity. In the EGFR-positive cases, the 5-year survival rates of patients with high TGF alpha and low TGF alpha were 36% and 85%, respectively (P less than 0.05). The 5-year survival rates of patients with high EGF and low EGF were 25% and 77%, respectively (P less than 0.05). In contrast, in the EGFR-negative cases, there was no statistical difference between the 5-year survival rates of patients with either high TGF alpha or EGF and low TGF alpha or EGF. Because autocrine growth mechanisms are present in adenocarcinoma of the human lung, these events may contribute to clarification of tumor development, and perhaps even to a better prognosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208175

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins.

Authors:  Benjamin J Hackel; Jason R Neil; Forest M White; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2011-12-09       Impact factor: 1.650

Review 3.  New perspectives in lung cancer. 2. Growth factors and lung cancer.

Authors:  P J Woll
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

4.  Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.

Authors:  H Dean Hosgood; Idan Menashe; Min Shen; Meredith Yeager; Jeff Yuenger; Preetha Rajaraman; Xingzhou He; Nilanjan Chatterjee; Neil E Caporaso; Yong Zhu; Stephen J Chanock; Tongzhang Zheng; Qing Lan
Journal:  Carcinogenesis       Date:  2008-08-01       Impact factor: 4.944

Review 5.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

6.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Authors:  Seok Jin Kim; Zahid N Rabbani; Fan Dong; Robin T Vollmer; Ernst-Gilbert Schreiber; Mark W Dewhirst; Zeljko Vujaskovic; Michael J Kelley
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

7.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

8.  MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targeting TGFA gene expression.

Authors:  Haijian Wu; Yan Liu; Xiao Ou Shu; Qiuyin Cai
Journal:  Carcinogenesis       Date:  2016-03-31       Impact factor: 4.944

9.  In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.

Authors:  C Liu; M S Tsao
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

10.  Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma.

Authors:  Jin-Hee Ahn; Sang-We Kim; Seung-Mo Hong; Cheolwon Suh; Woo Kun Kim; In Chul Lee; Jung-Shin Lee
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.